Polymer Capital Management HK LTD Increases Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

Polymer Capital Management HK LTD increased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 27.2% in the 4th quarter, Holdings Channel.com reports. The firm owned 36,765 shares of the biopharmaceutical company’s stock after buying an additional 7,865 shares during the quarter. Alnylam Pharmaceuticals comprises 2.1% of Polymer Capital Management HK LTD’s holdings, making the stock its 12th largest position. Polymer Capital Management HK LTD’s holdings in Alnylam Pharmaceuticals were worth $14,620,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in ALNY. HM Payson & Co. purchased a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at $27,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at $29,000. Ameriflex Group Inc. purchased a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at $32,000. Manchester Capital Management LLC boosted its stake in shares of Alnylam Pharmaceuticals by 600.0% in the fourth quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 72 shares during the period. Finally, Aster Capital Management DIFC Ltd purchased a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at $36,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Trading Down 2.3%

Alnylam Pharmaceuticals stock opened at $282.85 on Friday. The firm’s 50-day moving average is $304.31 and its 200-day moving average is $343.68. The company has a debt-to-equity ratio of 0.94, a quick ratio of 3.06 and a current ratio of 3.13. Alnylam Pharmaceuticals, Inc. has a 1 year low of $281.77 and a 1 year high of $495.55. The company has a market cap of $37.76 billion, a P/E ratio of 77.28 and a beta of 0.29.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The company had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same period last year, the firm posted ($0.44) EPS. The company’s revenue for the quarter was up 96.4% on a year-over-year basis. On average, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post 7.47 earnings per share for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, insider Melissa Mclaughlin sold 2,286 shares of the firm’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $330.42, for a total value of $755,340.12. Following the transaction, the insider directly owned 9,443 shares in the company, valued at approximately $3,120,156.06. This trade represents a 19.49% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David E. I. Pyott sold 3,830 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the transaction, the director owned 1,582 shares in the company, valued at approximately $473,302.76. The trade was a 70.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 7,740 shares of company stock worth $2,420,214. Insiders own 0.86% of the company’s stock.

Analyst Upgrades and Downgrades

ALNY has been the subject of several analyst reports. Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Wells Fargo & Company increased their price objective on shares of Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the company an “equal weight” rating in a research note on Friday, May 1st. Jefferies Financial Group reiterated a “hold” rating and set a $330.00 price objective (down from $522.00) on shares of Alnylam Pharmaceuticals in a research note on Monday, March 16th. Citigroup started coverage on shares of Alnylam Pharmaceuticals in a research note on Tuesday, May 19th. They set a “buy” rating and a $380.00 price objective on the stock. Finally, Chardan Capital reiterated a “buy” rating and set a $425.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 25th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $463.13.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.